(2R,4R,5R)-2-(2-amino-6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,4R,5R)-2-(2-amino-6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₀H₁₂ClN₅O₄
• 分子量: 301.69
• InChiKey: TXWHPSZYRUHEGT-ACJOCUEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS
  申请人：MODERNA THERAPEUTICS

  公开号：US20130156849A1

  公开（公告）日：2013-06-20

  The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

  本公开提供了包含修改的核酸分子的配方组合，这些核酸分子可能编码蛋白质、蛋白质前体或蛋白质或蛋白质前体的部分或完全加工形式的配方组合。该配方组合还可以包括一个修改的核酸分子和一个传递剂。本发明还提供了用于编码能够调节细胞功能和/或活性的多肽的核酸。
• MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
  申请人：Moderna Therapeutics, Inc.

  公开号：EP3505176A1

  公开（公告）日：2019-07-03

  The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

  本发明涉及制备、生产和治疗使用多核苷酸、初级转录本和 mmRNA 分子的组合物和方法。
• MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF
  申请人：modeRNA Therapeutics

  公开号：US20130115272A1

  公开（公告）日：2013-05-09

  The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.
• METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT
  申请人：modeRNA Therapeutics

  公开号：US20130165504A1

  公开（公告）日：2013-06-27

  The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules for their use in improving organ viability and/or longevity.
• SPLIT DOSE ADMINISTRATION
  申请人：MODERNA THERAPEUTICS

  公开号：US20130237594A1

  公开（公告）日：2013-09-12

  The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.